DHODH and multiple sclerosis: DHODH inhibitors have been suggested for treating diseases such as adjuvant arthritis [95], lymphoproliferation and systemic lupus erythematosus [96], graft-versus-host disease [97], tubulointerstitial nephritis [98], proteoglycan-induced arthritis [99], glomerulonephritis [99], myasthenia gravis [100], diabetes [101], psoriasis, autoimmune diseases, plasmodium, bacterial infections [102], rheumatoid arthritis [103] and multiple sclerosis (MS) [51, 104, 105], Miller syndrome [106], edema [107], and hippocampal networks related epilepsy [108].